Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Regimen in Newly Diagnosed Philadelphia Chromosome-Negative ALL in AYAs
NCT07227584Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2026
- Primary completion
- Jul 2030
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab, cyclophosphamide, cytarabine, dexamethasone, pegylated liposomal doxorubicin in acute lymphoblastic leukemia (ALL), sponsored by Dana-Farber Cancer Institute. Started Apr 2026; status: recruiting.
02
Drugs
blinatumomabcyclophosphamidecytarabinedexamethasonepegylated liposomal doxorubicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07227584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227584.